PF-07261271

N/A

Report date: 2025/12/18 17:36:19

Base Information

Drug NamePF-07261271
Drug Alias NamePF-07261271RG-6730
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-12 subunit beta inhibitorsTumor necrosis factor superfamily member 15 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12 subunit betaTumor necrosis factor superfamily member 15Interleukin-23
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesTelavant IncPfizer Inc
Inactive CompaniesN/A
Active IndicationsInflammatory Bowel Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A